Universal Health Services Inc (UHS)
Health Care · Health Care Facilities · US stock · S&P 500 component
$185.10
▼ -2.26 (1.21%)
Fair valueData under review
$761
$381fair band $533–$990$1,142
Day's range
$182.72 – $189.19
52-week range
$139.92 – $245.26
About Universal Health Services Inc
Universal Health Services operates hospitals and care facilities. Its acute care hospitals are located in the United States, and it runs a large behavioral health business with inpatient psychiatric hospitals and treatment centers in the United States and United Kingdom. Revenue comes from patient services paid by government programs, commercial insurers and individuals, so reimbursement rates and patient volumes matter.
Universal Health Services Inc generated $18.1 billion in revenue during the last twelve months. The three-year revenue growth rate is 9.0% a year. Operating margin stands at 11.4%, showing profit left after running costs. Return on invested capital stands at 13%. Net debt is 1.7 times of EBITDA. A dividend is paid, with a yield of 0.4%. The X-Ray Score is 66 out of 100.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $139.92 – $245.26Volume 585,600Daily, split-adjusted
Vitals
Market cap$11.1B
52-week range$139.92 – $245.26
Volume (last day)585,600
P/E (TTM)7.6
EBIT / EV yield13.0%
Free-cash-flow yield7.6%
Dividend yield0.4%
Revenue (TTM)$18.1B
Net income (TTM)$1.5B
Operating margin11.4%
Return on capital12.9%
Debt incl. leases$4.9B
Cash & securities$139M
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$761model spread $709 – $826
Data under review
+0.0% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is Medium, so the safety margin is 30%.
Price $185
Undervalued < $533Fair $533 – $990Overvalued > $990
10-year DCF (market-scaled)
$797
Peer multiples
$690
Earnings power floor (not blended)
$238
Fundamentals-adjusted multiple
$797
Growth the price implies
-6.5%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Read the lenses below
The price sits inside our fair-value band. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Strong
95/100
Cheap against its sector on earnings and cash flow.
See the numbers →
EBIT / EV yield13.0%
Free-cash-flow yield7.6%
Fair value vs price4.1×
Growth
Strong
76/100
Growing faster than most of its sector.
See the numbers →
Revenue growth (3y)9.0%
EPS growth (3y)36.2%
Growth consistency100%
Profitability
Weak
45/100
Earns lower returns on its capital than most peers.
See the numbers →
Return on invested capital12.9%
Operating margin11.4%
Financial health
Fair
63/100
Balance sheet is in typical shape for its sector.
See the numbers →
Piotroski F-Score8 / 9
Net debt / EBITDA1.7×
Interest cover13.1×
Dividends
Weak
31/100
Dividend is modest or less certain than peers.
See the numbers →
Dividend yield0.4%
Dividends vs free cash flow6%
Dividend growth-4.3%
Quarterly results: last 6 quarters
+6.7%
Mar '25
+9.6%
Jun '25
+13.4%
Sep '25
+9.1%
Dec '25
+9.6%
Mar '26
+8.3%
Jun '26
Revenue against the same quarter a year earlier. Latest quarter revenue $4.6B, diluted EPS $5.98.
Compare with peers
HCA HCA Healthcare, Inc.64Other Health Care Facilities companies by X-Ray Score.
Fundamentals checklist
● 8 Good · ● 3 Average · ● 3 BadCash quality
Earnings backed by cashBad
Free-cash-flow yieldGood
Risk models
Piotroski F-ScoreGood
Growth
EPS growth (3y)Good
Free-cash-flow growth (3y)Good
Revenue growth (3y)Good
Growth consistencyGood
Balance sheet
Current ratioBad
Net debt / EBITDAAverage
Interest coverAverage
Valuation
Fair value vs priceGood
EBIT / EV yieldGood
Profitability
Return on invested capitalAverage
Operating marginBad
Each check is graded against the company's sector, not a fixed number. Checklist score 64/100.
Financials
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $12.6B | $13.4B | $14.3B | $15.8B | $17.4B |
| Operating income | $1.4B | $1.0B | $1.2B | $1.7B | $2.0B |
| Net income | $992M | $676M | $718M | $1.1B | $1.5B |
| Operating cash flow | $884M | $996M | $1.3B | $2.1B | $1.9B |
| Operating margin | 10.8% | 7.5% | 8.2% | 10.6% | 11.5% |
| Free cash flow | $28M | $262M | $525M | $1.1B | $849M |
| Diluted EPS | $11.82 | $9.14 | $10.23 | $16.82 | $23.10 |
Fiscal years, from SEC filings.
Technical summary
Daily
Strongly bullish
12 bullish · 3 neutral · 1 bearish
Weekly
Strongly bullish
10 bullish · 1 neutral · 1 bearish
Monthly
Bullish
5 bullish · 1 neutral · 2 bearish
Moving averages (daily)
| SMA 10 | 179.7 | Bullish |
| EMA 10 | 181.2 | Bullish |
| SMA 20 | 178.3 | Bullish |
| EMA 20 | 178.9 | Bullish |
| SMA 50 | 175.3 | Bullish |
| EMA 50 | 174.5 | Bullish |
| SMA 100 | 163.5 | Bullish |
| EMA 100 | 172.4 | Bullish |
| SMA 200 | 178.1 | Bullish |
| EMA 200 | 176.4 | Bullish |
Oscillators (daily)
| RSI (14) | 63.41 | Neutral |
| MACD (12, 26) | 2.62 | Bullish |
| Momentum (12) | 6.22 | Bullish |
| Stochastic %K (14) | 68.24 | Neutral |
| Williams %R (14) | -31.76 | Neutral |
| CCI (20) | 165.1 | Bearish |
Pivot points (classic, last session)
S3 175.7 | S2 179.2 | S1 182.1 | Pivot 185.7 | R1 188.6 | R2 192.1 | R3 195.1 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
0.80 USD
Yield on today's price
0.43%
Frequency
Quarterly
Next ex-dividend date
Not announced
| Ex-dividend date | Amount per share |
|---|---|
| 1 Sep 2026 | 0.2000 |
| 8 Jun 2026 | 0.2000 |
| 2 Mar 2026 | 0.2000 |
| 1 Dec 2025 | 0.2000 |
| 2 Sep 2025 | 0.2000 |
| 2 Jun 2025 | 0.2000 |
| 3 Mar 2025 | 0.2000 |
| 3 Dec 2024 | 0.2000 |
| 3 Sep 2024 | 0.2000 |
| 3 Jun 2024 | 0.2000 |
| 29 Feb 2024 | 0.2000 |
| 30 Nov 2023 | 0.2000 |
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
UHS SEC filings
21 Aug 2026
8-KSEC EDGAR
Entered a material agreement
17 Aug 2026
8-KSEC EDGAR
Other events
13 Aug 2026
8-KSEC EDGAR
Entered a material agreement
13 Aug 2026
424B5SEC EDGAR
424B5
10 Aug 2026
424B5SEC EDGAR
424B5
7 Aug 2026
10-QSEC EDGAR
Quarterly report
28 Jul 2026
8-KSEC EDGAR
Results of operations
21 Jul 2026
8-KSEC EDGAR
Entered a material agreement
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.